<DOC>
	<DOCNO>NCT00331045</DOCNO>
	<brief_summary>This study intend investigate recommend dose alvimopan dose 0.25mg/day ( 0.25mg , OD ) , 0.5mg/day ( 0.25mg , BID ) 1mg/day ( 0.5mg , BID ) placebo 3 week patient receive opioids management cancer pain develop constipation , give overall consideration efficacy safety data treatment group . Also , efficacy safety data alvimopan recommend dose group compare placebo confirm alvimopan 's safety efficacy .</brief_summary>
	<brief_title>Clinical Evaluation Of Alvimopan ( SB767905 ) On Constipation And Related Symptoms Associated With Opioid</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Alvimopan</mesh_term>
	<criteria>Inclusion criterion : Have cancer . Taking opioid therapy continue intractable pain . Experiencing less bowel movement frequency compare opioid treatment . Must meet protocoldefinition opioidinduced constipation . Exclusion criterion : Gastrointestinal pelvic disorder know affect gastrointestinal function induce bowel transit disorder ileus . Subjects , investigator 's opinion , gastrointestinal dysfunction predominantly due cause use opioids .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Opioids</keyword>
	<keyword>cancer</keyword>
	<keyword>constipation</keyword>
</DOC>